Blocking the survival of the nastiest by HSP90 inhibition

被引：9
|
作者：
Workman, Paul [1 ]
Clarke, Paul A. [1 ]
Al-Lazikani, Bissan [1 ]
机构：
[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SW3 6JB, England
来源：
ONCOTARGET | 2016年 / 7卷 / 04期
关键词：
HSP90; CLONAL EVOLUTION; CANCER; RESISTANCE; THERAPY; MODELS;
D O I：
10.18632/oncotarget.6971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.
引用
收藏
页码：3658 / 3661
页数：4
相关论文
共 50 条
  • [11] Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
    Koay, Yen Chin
    Wahyudi, Hendra
    McAlpine, Shelli R.
    CHEMISTRY-A EUROPEAN JOURNAL, 2016, 22 (51) : 18572 - 18582
  • [12] Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (hsp90) inhibition: a significant advance on current hsp90 chemotherapies
    Koay, Yen Chin
    McConnell, Jeanette R.
    Wang, Yao
    McAlpine, Shelli R.
    RSC ADVANCES, 2015, 5 (73): : 59003 - 59013
  • [13] HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion
    Taiyab, Aftab
    Rao, Ch. Mohan
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2011, 1813 (01): : 213 - 221
  • [14] Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
    Park, Sangkyu
    Park, Jeong-A
    Jeon, Jae-Hyung
    Lee, Younghee
    BIOMOLECULES & THERAPEUTICS, 2019, 27 (05) : 423 - 434
  • [15] Overview: Translating Hsp90 Biology into Hsp90 Drugs
    Workman, Paul
    CURRENT CANCER DRUG TARGETS, 2003, 3 (05) : 297 - 300
  • [16] A comparison of Hsp90α and Hsp90β interactions with cochaperones and substrates
    Taherian, Aliakbar
    Krone, Patrick H.
    Ovsenek, Nick
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 2008, 86 (01): : 37 - 45
  • [17] Hsp90 inhibition sensitizes DLBCL cells to cisplatin
    Schmidt, Linnea
    Issa, Issa Ismail
    Haraldsdottir, Hulda
    Hald, Jonas Laugard
    Schmitz, Alexander
    Due, Hanne
    Dybkaer, Karen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 431 - 440
  • [18] Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
    Nethisinghe, Suran
    Abeti, Rosella
    Kesavan, Maheswaran
    Wigley, W. Christian
    Giunti, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [19] Inhibition of HSP90 molecular chaperones: moving into the clinic
    Garcia-Carbonero, Rocio
    Carnero, Amancio
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2013, 14 (09): : E358 - E369
  • [20] Hsp90 Inhibition Decreases Mitochondrial Protein Turnover
    Margineantu, Daciana H.
    Emerson, Christine B.
    Diaz, Dolores
    Hockenbery, David M.
    PLOS ONE, 2007, 2 (10):
12345